Department of Ophthalmology, Hospital of Ludwigshafen, Teaching Hospital of the University of Johannes Gutenberg-University Mainz, Mainz, Germany; Department of Ophthalmology, University Hospitals and School of Medicine, Geneva, Switzerland.
Department of Ophthalmology, University Hospitals and School of Medicine, Geneva, Switzerland.
Surv Ophthalmol. 2019 Jul-Aug;64(4):443-451. doi: 10.1016/j.survophthal.2019.01.011. Epub 2019 Jan 30.
The retinal ganglion cells infarcted in central retinal artery occlusion (CRAO) are the somata of the optic nerve axons, part of the central nervous system. Consequently, CRAO with inner retinal infarction is a small vessel stroke, usually with the devastating consequence of severe visual loss in the affected eye. At present, there is no generally accepted, evidence-based therapy of nonarteritic CRAO in contrast to ischemic cerebral stroke that has well-accepted treatment protocols. Widely divergent and controversial therapeutic options for CRAO reflect the desperation of treating physicians and disparate conflicting studies. We examine reasons why treatment of nonarteritic CRAO remains problematic and then suggest a provisional new approach to treatment based on updated understanding of CRAO pathophysiology and analysis of current therapeutic options and their rationales.
视网膜中央动脉阻塞(CRAO)中梗死的神经节细胞是视神经轴突的胞体,属于中枢神经系统的一部分。因此,伴有内层视网膜梗死的 CRAO 是小血管卒中,通常会导致受累眼严重视力丧失,后果严重。目前,与已被广泛接受并具有明确治疗方案的缺血性脑卒中不同,针对非动脉炎性 CRAO 还没有被普遍认可的循证医学治疗方法。CRAO 的治疗方法广泛存在差异且颇具争议,这反映出治疗医生的无奈和相互矛盾的研究结果。我们首先探讨了 CRAO 治疗仍然存在问题的原因,然后基于对 CRAO 病理生理学的最新认识以及对当前治疗选择及其合理性的分析,提出了一种治疗该病的新方法。